stockrow
Friday 6 November 2026
Export CRBP’s income statement to Excel — free account
Corbus Pharmaceuticals Holdings, Inc.
CRBP Healthcare Biotechnology
- EPS
- −25.7%
- Free cash flow
- −78.5%
Quarter to June 2026, against a year earlier
3.05
0.19
+6.64%
Follow CRBP
Alert me
Corbus Pharmaceuticals Holdings, Inc. (CRBP) P/E ratio
Corbus Pharmaceuticals Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| Dec 2020 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XBIT XBiotech Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| HRTX Heron Therapeutics, Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | n/m |
| CLNN Clene Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)